Pacific Biosciences of California Company Profile (NASDAQ:PACB)

About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:PACB
  • CUSIP: 69404D10
  • Web: www.pacb.com
Capitalization:
  • Market Cap: $590.67 million
  • Outstanding Shares: 115,591,000
Average Prices:
  • 50 Day Moving Avg: $4.61
  • 200 Day Moving Avg: $4.21
  • 52 Week Range: $3.08 - $9.44
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.86
  • P/E Growth: -0.20
Sales & Book Value:
  • Annual Revenue: $95.83 million
  • Price / Sales: 6.16
  • Book Value: $1.00 per share
  • Price / Book: 5.11
Profitability:
  • EBIDTA: ($75,400,000.00)
  • Net Margins: -89.67%
  • Return on Equity: -93.31%
  • Return on Assets: -57.10%
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 3.72%
  • Quick Ratio: 3.24%
Misc:
  • Average Volume: 1.03 million shs.
  • Beta: 2.06
  • Short Ratio: 17.03
 

Frequently Asked Questions for Pacific Biosciences of California (NASDAQ:PACB)

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The business earned $20.07 million during the quarter, compared to analyst estimates of $23.34 million. Pacific Biosciences of California had a negative net margin of 89.67% and a negative return on equity of 93.31%. The company's quarterly revenue was down 3.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.21) EPS. View Pacific Biosciences of California's Earnings History.

When will Pacific Biosciences of California make its next earnings announcement?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Pacific Biosciences of California.

Where is Pacific Biosciences of California's stock going? Where will Pacific Biosciences of California's stock price be in 2017?

2 analysts have issued twelve-month target prices for Pacific Biosciences of California's shares. Their predictions range from $8.00 to $12.00. On average, they expect Pacific Biosciences of California's stock price to reach $10.00 in the next twelve months. View Analyst Ratings for Pacific Biosciences of California.

What are analysts saying about Pacific Biosciences of California stock?

Here are some recent quotes from research analysts about Pacific Biosciences of California stock:

  • 1. According to Zacks Investment Research, "In the past six months, shares of Pacific Biosciences underperformed the broader industry in terms of price. The company posted an unimpressive second quarter of fiscal 2017, registering wider-than-expected loss. Of the other concerns, the DNA sequencing market is highly competitive owing to the presence of several established players. Cutthroat competition in the niche space is a headwind in our view. On the brighter side, solid contribution from the Instrument and Consumable revenue platforms is a significant positive. We are also upbeat about the higher margin sales of the SequelTM System. However, headwinds related to the limited availability of SMRT cells (Single Molecule, Real-Time) for the Sequel system and higher non-cash operating expenses are expected to mar prospects over the long haul. Meanwhile, the company witnessed significant strength in China. Notably, it has placed numerous system orders in the region with both new and existing customers." (8/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "Solid 4Q16 results despite lower than-expected Sequel bookings. The company reported total revenues of $25.7M, $2.5M above our estimate of $23.2M and $2.7M above FactSet consensus of $23.0M. System revenue beat due to strong placements in the quarter, slightly offset by lower-than-expected consumable revenue." (2/3/2017)

Who are some of Pacific Biosciences of California's key competitors?

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:

  • Michael W. Hunkapiller Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Susan K. Barnes, Chief Financial Officer, Executive Vice President, Principal Accounting Officer
  • Kevin P. Corcoran, Senior Vice President - Market Development
  • Michael Phillips, Senior Vice President - Research and Development
  • William W. Ericson, Lead Independent Director
  • David Botstein Ph.D., Independent Director
  • Brook H. Byers Ph.D., Independent Director
  • Randall Livingston, Independent Director
  • John F. Milligan Ph.D., Independent Director

Who owns Pacific Biosciences of California stock?

Pacific Biosciences of California's stock is owned by many different of retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (9.17%), Capital World Investors (6.78%), Vanguard Group Inc. (4.04%), State Street Corp (1.32%), Frontier Capital Management Co. LLC (1.61%) and Kennedy Capital Management Inc. (1.27%). View Institutional Ownership Trends for Pacific Biosciences of California.

Who sold Pacific Biosciences of California stock? Who is selling Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Lord Abbett & CO. LLC, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Ameriprise Financial Inc., Citadel Advisors LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Who bought Pacific Biosciences of California stock? Who is buying Pacific Biosciences of California stock?

Pacific Biosciences of California's stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Maverick Capital Ltd., Frontier Capital Management Co. LLC, Kennedy Capital Management Inc., Spark Investment Management LLC, Vanguard Group Inc., California Public Employees Retirement System and Trellus Management Company LLC. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy Pacific Biosciences of California stock?

Shares of Pacific Biosciences of California can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of Pacific Biosciences of California stock can currently be purchased for approximately $5.11.


MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pacific Biosciences of California (NASDAQ:PACB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $10.00 (95.69% upside)

Analysts' Ratings History for Pacific Biosciences of California (NASDAQ:PACB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00MediumView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHold$12.00N/AView Rating Details
6/27/2016CL KingInitiated CoverageBuy$11.00N/AView Rating Details
4/15/2016MKM PartnersInitiated CoverageNeutral$16.50N/AView Rating Details
4/14/2016First AnalysisInitiated CoverageOverweight$11.00N/AView Rating Details
2/5/2016StephensReiterated RatingBuyN/AView Rating Details
2/4/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$9.00 -> $11.00N/AView Rating Details
10/23/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Pacific Biosciences of California (NASDAQ:PACB)
Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Earnings History by Quarter for Pacific Biosciences of California (NASDAQ PACB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.22)N/AView Earnings Details
8/2/2017Q2 2017($0.24)($0.26)$23.34 million$20.07 millionViewListenView Earnings Details
4/26/2017Q1 2017($0.23)($0.26)$23.80 million$24.90 millionViewN/AView Earnings Details
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)$10.17 million$11.64 millionViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pacific Biosciences of California (NASDAQ:PACB)
2017 EPS Consensus Estimate: ($0.85)
2018 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.21)($0.19)($0.20)
Q2 20172($0.26)($0.24)($0.25)
Q3 20172($0.23)($0.18)($0.21)
Q4 20172($0.21)($0.17)($0.19)
Q1 20182($0.20)($0.19)($0.20)
Q2 20182($0.19)($0.18)($0.19)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacific Biosciences of California (NASDAQ:PACB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Pacific Biosciences of California (NASDAQ:PACB)
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 68.32%
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Institutional Ownership by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Insider Trades by Quarter for Pacific Biosciences of California (NASDAQ:PACB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.00View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.00View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Pacific Biosciences of California (NASDAQ:PACB)
Latest Headlines for Pacific Biosciences of California (NASDAQ:PACB)
Source:
DateHeadline
prnewswire.com logoNext-Generation Sequencing Market by Product, Services, & Application - Global Forecasts to 2022
www.prnewswire.com - September 14 at 8:55 AM
americanbankingnews.com logo$28.49 Million in Sales Expected for Pacific Biosciences of California, Inc. (PACB) This Quarter
www.americanbankingnews.com - September 14 at 8:48 AM
americanbankingnews.com logoCritical Review: Pacific Biosciences of California (PACB) and its Rivals
www.americanbankingnews.com - September 12 at 11:00 AM
americanbankingnews.com logo Brokerages Anticipate Pacific Biosciences of California, Inc. (PACB) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - September 12 at 6:34 AM
seekingalpha.com logoPacific Biosciences of California (PACB) Presents At Photonics Summit and Workshop - Slideshow
seekingalpha.com - September 7 at 7:24 AM
americanbankingnews.com logo-$0.20 Earnings Per Share Expected for Pacific Biosciences of California, Inc. (PACB) This Quarter
www.americanbankingnews.com - August 24 at 6:20 PM
seekingalpha.com logoPacific Biosciences Is Advancing Genomics
seekingalpha.com - August 19 at 6:22 AM
americanbankingnews.com logoZacks Investment Research Downgrades Pacific Biosciences of California, Inc. (PACB) to Hold
www.americanbankingnews.com - August 10 at 3:03 PM
americanbankingnews.com logoPacific Biosciences of California, Inc. Expected to Earn FY2017 Earnings of ($0.95) Per Share (NASDAQ:PACB)
www.americanbankingnews.com - August 10 at 10:42 AM
americanbankingnews.com logoPacific Biosciences of California, Inc. (NASDAQ:PACB) Expected to Announce Quarterly Sales of $28.33 Million
www.americanbankingnews.com - August 8 at 7:44 AM
fool.com logoWhat's Behind Pacific Biosciences of California's Stock Rally Today?
www.fool.com - August 8 at 5:58 AM
finance.yahoo.com logoWhat's Behind Pacific Biosciences of California's Stock Rally Today?
finance.yahoo.com - August 8 at 5:58 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Pacific Biosciences of California, Inc. Boosted by Analyst (NASDAQ:PACB)
www.americanbankingnews.com - August 7 at 7:34 AM
finance.yahoo.com logoPacific Biosciences of California, Inc. breached its 50 day moving average in a Bullish Manner : PACB-US : August 4, 2017
finance.yahoo.com - August 6 at 7:49 PM
americanbankingnews.com logo Analysts Anticipate Pacific Biosciences of California, Inc. (PACB) to Post -$0.21 Earnings Per Share
www.americanbankingnews.com - August 6 at 8:52 AM
americanbankingnews.com logoPacific Biosciences of California, Inc. (PACB) Forecasted to Earn Q2 2018 Earnings of ($0.18) Per Share
www.americanbankingnews.com - August 4 at 4:54 PM
finance.yahoo.com logoInvestor Network: Pacific Biosciences of California, Inc. to Host Earnings Call
finance.yahoo.com - August 4 at 6:48 AM
finance.yahoo.com logoPacBio Announces New Agreement with Novogene to Purchase Ten Sequel Systems
finance.yahoo.com - August 4 at 6:48 AM
finance.yahoo.com logoHere's Why Pacific Biosciences of California Is Surging Today
finance.yahoo.com - August 4 at 6:48 AM
finance.yahoo.com logoPacific Biosciences of California, Inc. – Value Analysis (NASDAQ:PACB) : August 4, 2017
finance.yahoo.com - August 4 at 6:48 AM
fool.com logoHere's Why Pacific Biosciences of California Is Surging Today
www.fool.com - August 3 at 4:11 PM
fool.com logoPacific Biosciences of California Struggles in the Second Quarter With Lower Sales
www.fool.com - August 3 at 10:03 AM
prnewswire.com logoBreakfast Technical Briefing on Biotech Stocks -- Pacific Biosciences of California, Puma Biotechnology, PDL ... - PR Newswire (press release)
www.prnewswire.com - August 3 at 6:43 AM
nasdaq.com logoPacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - August 3 at 6:43 AM
finance.yahoo.com logoEdited Transcript of PACB earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 6:43 AM
finance.yahoo.com logoPacific Biosciences reports 2Q loss
finance.yahoo.com - August 3 at 6:43 AM
americanbankingnews.com logoPacific Biosciences of California, Inc. (PACB) Announces Earnings Results
www.americanbankingnews.com - August 2 at 11:16 PM
finance.yahoo.com logoPacific Biosciences of California, Inc. Second Quarter 2017 Financial Results Call
finance.yahoo.com - July 25 at 12:53 AM
finance.yahoo.com logoPacific Biosciences of California, Inc. breached its 50 day moving average in a Bearish Manner : PACB-US : July 20, 2017
finance.yahoo.com - July 21 at 6:02 AM
americanbankingnews.com logo$23.27 Million in Sales Expected for Pacific Biosciences of California, Inc. (PACB) This Quarter
www.americanbankingnews.com - July 19 at 3:46 PM
streetinsider.com logoNovogene and Pacific Biosciences (PACB) to Jointly Develop, Co-Market Novel Applications Based on Sequel Platform - StreetInsider.com
www.streetinsider.com - July 19 at 1:47 AM
finance.yahoo.com logoNovogene and Pacific Biosciences to Jointly Develop and Co-Market Novel Applications Based on Sequel Platform
finance.yahoo.com - July 19 at 1:47 AM
americanbankingnews.com logo-$0.24 EPS Expected for Pacific Biosciences of California, Inc. (NASDAQ:PACB) This Quarter
www.americanbankingnews.com - July 17 at 10:49 AM
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : July 5, 2017
finance.yahoo.com - July 6 at 7:47 AM
americanbankingnews.com logoPacific Biosciences of California, Inc. (PACB) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - June 27 at 2:52 PM
americanbankingnews.com logoAnalysts Issue Forecasts for Pacific Biosciences of California, Inc.'s FY2018 Earnings (PACB)
www.americanbankingnews.com - June 26 at 8:16 AM
americanbankingnews.com logoZacks: Brokerages Expect Pacific Biosciences of California, Inc. (PACB) Will Post Quarterly Sales of $23.27 Million
www.americanbankingnews.com - June 23 at 7:24 PM
finance.yahoo.com logoPacBio Technology Resolves Complex Maize Genome, Driving Demand for Other Large-Scale AgBio Sequencing Projects
finance.yahoo.com - June 22 at 7:31 AM
americanbankingnews.com logoPacific Biosciences of California, Inc. (PACB) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - June 21 at 8:02 AM
nasdaq.com logoPacific Biosciences (PACB) Prices Offering of Common Stock - Nasdaq
www.nasdaq.com - June 17 at 7:49 PM
reuters.com logoBRIEF-Pacific Biosciences of California reports proposed public offering of common stock
www.reuters.com - June 16 at 8:41 AM
streetinsider.com logoPacific Bio (PACB) Prices 15.42M Share Offering at $3.10/Sh
www.streetinsider.com - June 16 at 8:41 AM
rttnews.com logoPacific Biosciences Of California Prices Offering At $3.10/Share
www.rttnews.com - June 16 at 8:41 AM
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : June 14, 2017
finance.yahoo.com - June 14 at 11:16 PM
americanbankingnews.com logoPacific Biosciences of California, Inc. (PACB) Downgraded by ValuEngine
www.americanbankingnews.com - June 13 at 3:28 PM
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : June 1, 2017
finance.yahoo.com - June 1 at 3:20 PM
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 6:19 PM
finance.yahoo.com logoRecent Publications Demonstrate Rapid Adoption of SMRT Sequencing for Plant and Animal Transcriptome Analysis
finance.yahoo.com - May 22 at 9:43 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Pacific Biosciences of California's FY2017 Earnings (PACB)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to Pacific Biosciences of California, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 7:35 PM

Social

Chart

Pacific Biosciences of California (PACB) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff